ImmunityBio (IBRX) Receivables (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Receivables of $43.3 million for Q1 2026, up 153.14% year-over-year from $17.1 million in Q1 2025, and up 1.54% quarter-over-quarter from $42.6 million in Q4 2025.
ImmunityBio (IBRX) Receivables (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Receivables for 8 consecutive years, with $43.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables rose 153.14% year-over-year to $43.3 million; the TTM figure through Mar 2026 stood at $43.3 million (up 153.14% YoY), while the FY2025 annual figure was $42.6 million, up 1564.73% from the prior year.
- Receivables improved to $43.3 million in Q1 2026 per IBRX's latest filing, from $42.6 million in the prior quarter.
- Across five years, Receivables topped out at $43.3 million in Q1 2026 and bottomed at $2.0 million in Q4 2023.
- Historically, Receivables has averaged $14.1 million across 5 years, with a median of $3.6 million in 2023.
- Annual changes were most pronounced in 2023 — Receivables slumped 36.71% — and 2025, when it jumped 1564.73%.
- ImmunityBio's Receivables stood at $3.2 million in 2022, then plunged by 36.71% to $2.0 million in 2023, then gained by 26.8% to $2.6 million in 2024, then surged by 1564.73% to $42.6 million in 2025, then climbed by 1.54% to $43.3 million in 2026.
- Business Quant data shows IBRX's Receivables at $43.3 million in Q1 2026, $42.6 million in Q4 2025, and $33.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | ImmunityBio | 7.97 Bn | 7.62 Bn | 50.94 Mn | 53.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.50 Mn |
| Mar 31, 2026 | 43.27 Mn |
| Dec 31, 2025 | 42.62 Mn |
| Sep 30, 2025 | 33.70 Mn |
| Jun 30, 2025 | 22.20 Mn |
| Mar 31, 2025 | 17.10 Mn |
| Dec 31, 2024 | 2.56 Mn |
| Sep 30, 2024 | 4.90 Mn |
| Jun 30, 2024 | 2.06 Mn |
| Mar 31, 2024 | 3.44 Mn |
| Dec 31, 2023 | 2.02 Mn |
| Sep 30, 2023 | 3.63 Mn |
| Jun 30, 2023 | 2.63 Mn |
| Dec 31, 2022 | 3.19 Mn |
| Jun 30, 2016 | 1.43 Mn |
| Jun 30, 2015 | 45,000.00 |
| Dec 31, 2014 | 145,000.00 |